ArticleScientific reports2025
Loss of adhesion impairs invasiveness and cell survival, contributing to the antimetastatic effect of cysteine proteases from Vasconcella cundinamarcensis in melanoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on available evidence showing the antitumoral/antimetastatic activity of the proteolytic fraction (P1G10) from Vasconcellea cundinamarcensis, we analyze possible mechanisms involved in the antimetastasic effect of this fraction and subfractions (CMS1, CMS2) after incubation with B16F10 melanoma cells in vitro and in vivo under sub-apoptotic conditions. The goal was to investigate potential mediators of the antitumoral/antimetastatic effect of P1G10 triggered before the onset of apoptosis. In B16F10 preincubated viable cells, it was observed changes in adhesion to ECM (extracellular matrix), reduced activity of metalloproteases and invasivity, reduction of pAkt and pErk mostly affecting the rate of lung metastasis in mice injected with B16F10 treated cells. In most of these assays the effects depend of the proteolytic activity of the fractions. Unexpectedly, the CMS2-IAA (CMS2 with proteolytically activity inhibited by iodoacetamide), enhanced pErk phosphorylation and increased procaspase-3 levels. The invasivity of B16F10 was impaired following incubation with the proteolytic fraction without affecting cell viability under the conditions analyzed. In conclusion, CMS2 reduces in vitro cell invasion and metastasis in murine melanoma B16F10.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.